Concepts (97)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antifungal Agents | 13 | 2023 | 16 | 2.720 |
Why?
|
| Candidemia | 7 | 2023 | 9 | 2.230 |
Why?
|
| Candida | 8 | 2023 | 10 | 2.170 |
Why?
|
| Echinocandins | 8 | 2023 | 8 | 1.340 |
Why?
|
| Candida glabrata | 3 | 2018 | 3 | 0.940 |
Why?
|
| Candidiasis | 5 | 2022 | 5 | 0.870 |
Why?
|
| Microbial Sensitivity Tests | 9 | 2019 | 96 | 0.680 |
Why?
|
| Lipopeptides | 3 | 2023 | 9 | 0.630 |
Why?
|
| Mutation | 3 | 2015 | 132 | 0.590 |
Why?
|
| Blood | 1 | 2018 | 4 | 0.580 |
Why?
|
| Microbiological Techniques | 1 | 2018 | 6 | 0.580 |
Why?
|
| Fungal Proteins | 2 | 2015 | 3 | 0.550 |
Why?
|
| Drug Resistance, Fungal | 2 | 2014 | 3 | 0.490 |
Why?
|
| Voriconazole | 1 | 2015 | 1 | 0.470 |
Why?
|
| Humans | 17 | 2023 | 4936 | 0.440 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2013 | 20 | 0.410 |
Why?
|
| Amphotericin B | 1 | 2012 | 2 | 0.390 |
Why?
|
| Catheter-Related Infections | 1 | 2012 | 5 | 0.390 |
Why?
|
| Anti-Bacterial Agents | 3 | 2019 | 176 | 0.360 |
Why?
|
| Candidiasis, Invasive | 2 | 2022 | 3 | 0.300 |
Why?
|
| Staphylococcal Infections | 2 | 2019 | 7 | 0.290 |
Why?
|
| beta-Lactams | 2 | 2019 | 12 | 0.290 |
Why?
|
| Vancomycin | 2 | 2019 | 28 | 0.290 |
Why?
|
| Bacteremia | 2 | 2019 | 10 | 0.280 |
Why?
|
| Middle Aged | 7 | 2019 | 967 | 0.270 |
Why?
|
| Treatment Outcome | 4 | 2019 | 177 | 0.260 |
Why?
|
| Aged, 80 and over | 4 | 2018 | 262 | 0.250 |
Why?
|
| Sensitivity and Specificity | 2 | 2018 | 126 | 0.240 |
Why?
|
| Male | 8 | 2019 | 2491 | 0.220 |
Why?
|
| Patient Discharge | 1 | 2022 | 18 | 0.190 |
Why?
|
| Aged | 5 | 2018 | 703 | 0.190 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 2 | 2019 | 5 | 0.190 |
Why?
|
| Diagnostic Tests, Routine | 2 | 2018 | 3 | 0.170 |
Why?
|
| Female | 7 | 2019 | 2523 | 0.170 |
Why?
|
| Mycoses | 1 | 2019 | 2 | 0.160 |
Why?
|
| Azoles | 1 | 2019 | 1 | 0.150 |
Why?
|
| Triazoles | 1 | 2019 | 5 | 0.150 |
Why?
|
| Fungi | 1 | 2019 | 7 | 0.150 |
Why?
|
| Bacterial Load | 1 | 2018 | 8 | 0.140 |
Why?
|
| Peritonitis | 1 | 2018 | 2 | 0.140 |
Why?
|
| Ceftriaxone | 1 | 2018 | 4 | 0.140 |
Why?
|
| Bacterial Infections | 1 | 2018 | 6 | 0.140 |
Why?
|
| Antimicrobial Stewardship | 1 | 2018 | 3 | 0.140 |
Why?
|
| Medical Overuse | 1 | 2017 | 1 | 0.140 |
Why?
|
| Fluconazole | 1 | 2017 | 1 | 0.140 |
Why?
|
| Inappropriate Prescribing | 1 | 2017 | 2 | 0.140 |
Why?
|
| Asymptomatic Infections | 1 | 2017 | 2 | 0.140 |
Why?
|
| Urinary Tract Infections | 1 | 2017 | 5 | 0.140 |
Why?
|
| Time Factors | 1 | 2018 | 163 | 0.140 |
Why?
|
| Bacteria | 1 | 2018 | 47 | 0.140 |
Why?
|
| beta-Glucans | 1 | 2015 | 1 | 0.120 |
Why?
|
| Immunity, Innate | 1 | 2015 | 8 | 0.120 |
Why?
|
| Cell Line | 1 | 2015 | 84 | 0.110 |
Why?
|
| Adult | 3 | 2018 | 1567 | 0.110 |
Why?
|
| Treatment Failure | 1 | 2014 | 7 | 0.110 |
Why?
|
| Patient Outcome Assessment | 1 | 2014 | 2 | 0.110 |
Why?
|
| Prognosis | 1 | 2014 | 60 | 0.110 |
Why?
|
| Colony Count, Microbial | 1 | 2013 | 13 | 0.100 |
Why?
|
| Risk Factors | 1 | 2014 | 159 | 0.100 |
Why?
|
| Animals | 2 | 2019 | 1711 | 0.100 |
Why?
|
| Communicable Diseases | 1 | 2012 | 6 | 0.100 |
Why?
|
| Glucosyltransferases | 1 | 2012 | 2 | 0.100 |
Why?
|
| Periodicals as Topic | 1 | 2012 | 8 | 0.100 |
Why?
|
| Anti-Infective Agents | 1 | 2012 | 15 | 0.090 |
Why?
|
| Mice | 1 | 2015 | 685 | 0.090 |
Why?
|
| Retrospective Studies | 3 | 2019 | 341 | 0.090 |
Why?
|
| Young Adult | 1 | 2014 | 787 | 0.080 |
Why?
|
| Drug Therapy, Combination | 2 | 2019 | 26 | 0.070 |
Why?
|
| Hospitalization | 2 | 2015 | 38 | 0.050 |
Why?
|
| Candida albicans | 1 | 2019 | 1 | 0.040 |
Why?
|
| Virulence | 1 | 2019 | 6 | 0.040 |
Why?
|
| Species Specificity | 1 | 2019 | 14 | 0.040 |
Why?
|
| Animals, Genetically Modified | 1 | 2019 | 12 | 0.040 |
Why?
|
| Biopsy | 1 | 2019 | 13 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2019 | 4 | 0.040 |
Why?
|
| Acute Kidney Injury | 1 | 2019 | 14 | 0.040 |
Why?
|
| Drosophila melanogaster | 1 | 2019 | 45 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2018 | 5 | 0.040 |
Why?
|
| Clinical Audit | 1 | 2018 | 1 | 0.040 |
Why?
|
| Hospitals | 1 | 2018 | 10 | 0.040 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2018 | 16 | 0.040 |
Why?
|
| Prevalence | 1 | 2018 | 66 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2018 | 81 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2017 | 9 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 225 | 0.030 |
Why?
|
| Logistic Models | 1 | 2017 | 64 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2017 | 115 | 0.030 |
Why?
|
| United States | 1 | 2018 | 495 | 0.030 |
Why?
|
| Hospitals, Community | 1 | 2015 | 1 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2015 | 5 | 0.030 |
Why?
|
| Risk | 1 | 2014 | 34 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2014 | 111 | 0.030 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2014 | 47 | 0.030 |
Why?
|
| Peer Review | 1 | 2012 | 2 | 0.020 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2012 | 6 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2012 | 19 | 0.020 |
Why?
|
| HIV Infections | 1 | 2012 | 104 | 0.020 |
Why?
|